HK$5.51
1.08%
Hong Kong, Sep 28, 03:59 pm HKT. Closed.
ISIN
KYG8167W1380
Symbol
1177

Sino Biopharmaceutical Stock price

HK$5.50
-0.10 1.79% 1M
-0.36 6.07% 6M
-0.69 11.08% YTD
-2.57 31.82% 1Y
+2.69 95.55% 3Y
-0.73 11.66% 5Y
+3.19 138.68% 10Y
+5.32 3,043.59% 20Y
Hong Kong, Closing price Mon, Sep 28 2026
-0.08 1.35%
ISIN
KYG8167W1380
Symbol
1177
Industry

AI Insights on Sino Biopharmaceutical Insights AI Insights on Sino Biopharmaceutical

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Sino Biopharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$99.5b
Enterprise Value
HK$87.4b
Net debt
positive
Cash
HK$32.2b
Shares outstanding
17.8b
Valuation (TTM | estimate)
P/E
37.1
P/S
2.5 | 2.3
EV/Sales
2.2 | 2.0
EV/FCF
-
P/B
2.6
Dividends
DPS
HK$0.12
Yield 1Y | 5Y
2.2% | 1.9%
Growth 1Y | 5Y
33.3% | 14.9%
Payout 1Y | 3Y
80.0% | 52.9%
Increased
2 Years
Financials (TTM | estimate)
Revenue
HK$39.4b | HK$43.7b
EBITDA
-
EBIT
HK$11.7b
Net Income
HK$2.8b
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
10.3% | 17.4%
EBITDA
-
EBIT
89.0%
Net Income
-38.3%
Free Cash Flow
-
Margin
Gross
82.4%
EBITDA
-
EBIT
29.7%
Net
7.1%
Free Cash Flow
-
Financial Health
Equity Ratio
40.4%
Return on Equity
7.6%
ROCE
17.8%
ROIC
20.9%
Debt/Equity
0.5
More
EPS
HK$0.2
FCF per Share
-
Short interest
-
Employees
21k
Rev per Employee
HK$1.7m

Sino Biopharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Sino Biopharmaceutical forecast:

29x Buy
94%
2x Hold
6%

Analyst Opinions

31 Analysts have issued a Sino Biopharmaceutical forecast:

Buy
94%
Hold
6%

Financial data from Sino Biopharmaceutical

Jun '26
+/-
%
39,379 39,379
10% 10%
100%
- Direct Costs 6,921 6,921
6% 6%
18%
32,458 32,458
11% 11%
82%
- Selling and Administrative Expenses 13,813 13,813
8% 8%
35%
- Research and Development Expense 6,728 6,728
1% 1%
17%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 11,681 11,681
89% 89%
30%
Net Profit 2,792 2,792
38% 38%
7%

In millions HKD.

Don't miss a Thing! We will send you all news about Sino Biopharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sino Biopharmaceutical Stock News

Positive
Reuters
●
3 months ago
Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China ​unit had secured rights to ‌market two respiratory drugs from British company GSK in mainland China.
Positive
WSJ
●
3 months ago
Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments.
Positive
Reuters
●
3 months ago
Hong Kong-listed Sino Biopharmaceutical said on Wednesday it ​has granted AstraZeneca the ‌rights to develop a drug designed to treat chronic respiratory ​diseases outside China for ​total payments of up to $1.9 ⁠billion.

Company Profile

Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long term investments. The Other segment includes a research and development sector, which provides services to third-parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse on February 2, 2000 and is headquartered in Hong Kong.

Head office Cayman Islands
CEO Mr. Tse
Employees 21,435
Founded 2000
Website www.sinobiopharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today